CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients

Journal of Infectious Diseases

Volumn 198, Issue 6, 2008, Pages 843-850

  Read, Sarah W ^a,e   Lempicki, Richard A ^d   Di Mascio, Michele ^a   Srinivasula, Sharat ^c   Burke, Rosanne ^a   Sachau, William ^a   Bosche, Marjorie ^d   Adelsberger, Joseph W ^d   Sereti, Irini ^a   Davey Jr , Richard T ^a   Tavel, Jorge A ^a   Huang, Chiung Yu ^a   Issaq, Haleem J ^c   Fox, Stephen D ^c   Lane, H Clifford ^a   Kovacs, Joseph A ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SAIC FREDERICK INC   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DEUTERIUM; INTERLEUKIN 2 RECEPTOR ALPHA; RECOMBINANT INTERLEUKIN 2;

ANTIGEN EXPRESSION; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL LABELING; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE;

BLOOD GLUCOSE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CELL SURVIVAL; DEUTERIUM; GLUCOSE; HIV INFECTIONS; HUMANS; INTERLEUKIN-2; LYMPHOCYTE COUNT; PATIENT SELECTION;

EID: 51749108013     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/591250     Document Type: Article

References (15)

1. Kovacs JA, Vogel S, Albert JM, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-6.
2. Davey RT Jr, Chaitt DG, Albert JM, et al. A randomized trial of high-versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179:849-58.
3. Levy Y, Capitant C, Houhou S, et al. Comparison of subcutaneous and intravenous interleukin-2 in asymptomatic HIV-1 infection: a randomised controlled trial. ANRS 048 Study Group. Lancet 1999; 353:1923-9.
4. Davey RT Jr, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 2000; 284:183-9.
5. + T cells. Blood 2002; 100:2159-67.
6. + T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004; 104:775-80.
7. + T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115:2139-48.
8. Sereti I, Imamichi H, Natarajan V, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest 2005; 115:1839-47.
9. Hellerstein MK. Measurement of T-cell kinetics: recent methodologic advances. Immunol Today 1999; 20:438-41.
10. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22. Available at: http://www.jstor.org/ stable/2336267. Accessed 29 July 2008.
11. + T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis 2007; 196:677-83.
12. + T cells. Clin Immunol 2003; 106:188-96.
13. + T cell count predicts response to subcutaneous recombinant interleukin-2. Clin Infect Dis 2003; 37:e115-20.
14. Fox Z, Antunes F, Davey R, et al. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥300 cells/μL who were assigned to 7.5 MIU interleukin-2. HIV Med 2007; 8:112-23.
15. Ribeiro RM, Mohri H, Ho DD, Perelson AS. Modeling deuterated glucose labeling of T-lymphocytes. Bull Math Biol 2002; 64:385-405.